Measuring the value of pharmacogenomics (original) (raw)

• Collins, F. S. Shattuck lecture — Medical and societal consequences of the human genome project. N. Engl. J. Med. 341, 28–37 (1999).
  Article CAS Google Scholar
• Collins, F. S. & McKusick, V. A. Implications of the human genome project for medical science. JAMA 285, 540–544 (2001).
  Article CAS Google Scholar
• Varmus, H. Getting ready for gene-based medicine. N. Engl. J. Med. 347, 1526–1527 (2002).
  Article Google Scholar
• Khoury, M. J., McCabe, L. L. & McCabe, E. R. Population screening in the age of genomic medicine. N. Engl. J. Med. 348, 50–58 (2003).
  Article CAS Google Scholar
• Phillips, K. A. & Van Bebber, S. L. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med. Care Res. Rev. (in the press).
• Phillips, K. A., Van Bebber, S. L., Veenstra, D. & Sakowski, J. The economics of pharmacogenomics. Curr. Pharmacogenomics 1, 277–284 (2003).
  Article CAS Google Scholar
• Phillips, K. A., Veenstra, D., Van Bebber, S. L. & Sakowski, J. An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics. Pharmacogenomics 4, 231–239 (2003). Provides an overview of methods for analysing the value of pharmacogenomics.
  Article Google Scholar
• Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286, 2270–2279 (2001).
  Article CAS Google Scholar
• Phillips, K. A., Veenstra, D. L., Ramsey, S. D., Van Bebber, S. L. & Sakowski, J. Genetic testing and pharmacogenomics: issues for determining the impact to health care delivery and costs. Am. J. Manag. Care 10, 425–432 (2004).
  PubMed Google Scholar
• Veenstra, D. L., Higashi, M. K. & Phillips, K. A. Assessing the cost-effectiveness of pharmacogenomics. Pharm. Sci. 2 [online], <http://www.aapspharmsci.org/articles/ps0203/ps020329/ps020329.pdf> (2000).
• Danzon, P. & Towse, A. The economics of gene therapy and of pharmacogenetics. Value Health 5, 5–13 (2002).
  Article Google Scholar
• Robertson, J. A., Brody, B., Buchanan, A., Kahn, J. & McPherson, E. Pharmacogenetic challenges for the health care system. Health Affairs 21, 155–167 (2002).
  Article Google Scholar
• Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857–895 (2000).
  Article CAS Google Scholar
• Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250, 186–200 (2001).
  Article CAS Google Scholar
• Fishbain, D. A. et al. Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review. Pain Medicine 5, 81–93 (2004).
  Article Google Scholar
• Shah, J. Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare. Nature Biotechnol. 21, 747–753 (2003).
  Article CAS Google Scholar
• Evans, W. & Relling, M. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487–491 (1999).
  Article CAS Google Scholar
• Holtzman, N. & Marteau, T. Will genetics revolutionize medicine? N. Engl. J. Med. 343, 141–144 (2000).
  Article CAS Google Scholar
• Holtzman, N. A. & Marteau, T. M. Will genetics revolutionalize medicine? Author response. N. Engl. J. Med. 343, 1498 (2000).
  Article Google Scholar
• Lindpaintner, K. Pharmacogenetics and the future of medical practice. J. Mol. Med. 81, 141–153 (2003).
  Article Google Scholar
• Issa, A. M. Ethical perspectives on pharmacogenomic profiling in the drug development process. Nature Rev. Drug Discov. 1, 300–308 (2002).
  Article CAS Google Scholar
• Issa, A. M. Ethical considerations in clinical pharmacogenomics research. Trends Pharm. Sci. 21, 247–249 (2000).
  Article CAS Google Scholar
• Clayton, E. W. Ethical, legal, and social implications of genomic medicine. N. Engl. J. Med. 349, 562–569 (2003).
  Article Google Scholar
• Ries Merikangas, K. & Risch, N. Genomic priorities and public health. Science 302, 599–601 (2004). Evaluates the population impact of genomics on complex diseases.
  Article Google Scholar
• Haga, S. B. & Burke, W. Using pharmacogenetics to improve drug safety and efficacy. JAMA 291, 2869–2871 (2004). Assesses need for evidence and incentives to move pharmacogenomics forward.
  Article CAS Google Scholar
• Webster, A., Martin, P., Lewis, G. & Smart, A. Integrating pharmacogenetics into society: in search of a model. Nature Rev. Genet. 5, 663–669 (2004).
  Article CAS Google Scholar
• Food and Drug Administration. FDA clears first of kind genetic lab test [online], <http://www.fda.gov/bbs/topics/news/2004/new01149.html> (2004).
• Lesko, L. J. & Woodcock, J. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Rev. Drug Discov. 3, 763–769 (2004).
  Article CAS Google Scholar
• Food and Drug Administration. Guidance for industry: pharmacogenomic data submissions [online], <http://www.fda.gov/cber/gdlns/pharmdtasub.pdf> (2005).
• Lesko, L. J. et al. Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J. Clin. Pharmacol. 43, 342–358 (2003).
  Article CAS Google Scholar
• Salerno, R. A. & Lesko, L. J. Pharmacogenomics in drug development and regulatory decision-making: the Genomic Data Submission (GDS) proposal. Pharmacogenomics 5, 25–30 (2004).
  Article Google Scholar
• FDC Reports. FDA Pharmacogenomics Advisory Committee Will Oversee Data Submission. The Pink Sheet 22 March (2004).
• US Department of Health and Human Services & Food and Drug Administration. Innovation or Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products [online], <http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html> (2004).
• Secretary's Advisory Committee on Genetics Health and Society. Second Meeting, October 22–23 (2003).
• Gutman, S. OIVD requests a meeting with Roche Diagnostics regarding the AmpliChip CYP450 Microarray. [online], <http://www.fda.gov/cdrh/oivd/letter-roche2.html> (2003).
• Kaiser, J. FDA puts the brakes on Roche's gene array Test. Science 302, 1134 (2003).
  Article CAS Google Scholar
• Steimer, W. & Potter, J. M. Pharmacogenetic screening and therapeutic drugs. Clin. Chim. Acta 315, 137–155 (2002).
  Article CAS Google Scholar
• Phillips, K. A., Veenstra, D. L. & Sadee, W. Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy. Health Services Research 35, 1–12 (2000).
  Google Scholar
• Phillips, K. A. & Van Bebber, S. L. Cost-effectiveness of pharmacogenomic interventions: a systematic review of the literature. Pharmacogenomics 5, 1139–1149 (2004). Provides a review of cost-effectiveness analyses to date.
  Article Google Scholar
• Gold, M., Siegel, J., Russell, L. & Weinstein, M. Cost-Effectiveness in Health And Medicine (Oxford Univ. Press, New York, 1996).
  Google Scholar
• Drummond, M. F. Cost-of-illness studies — a major headache. Pharmacoeconomics 2, 1–4 (1992).
  Article CAS Google Scholar
• Rice, D. P. Estimating the cost of illness. (Public Health Service publication, US Gov. Printing Office, 1966).
  Google Scholar
• Rice, D. P. Cost of illness studies: what is good about them? Inj. Prev. 6, 177–179 (2000).
  Article CAS Google Scholar
• Varmus, H. Evaluating the burden of disease and spending the research dollars of the National Institutes of Health. N. Engl. J. Med. 340, 1914–15 (1999).
  Article CAS Google Scholar
• Wolf, C. & Smith, G. Pharmacogenetics. Br. Med. Bull. 55, 366–386 (1999).
  Article CAS Google Scholar
• European Society of Human Genetics. Polymorphic sequence variants in medicine: technical, social, legal and ethical issues — pharmacogenomics as an example. Background document. (Draft Version as per June 10, 2004) [online], <http://www.eshg.org/ESHG-IPTSPGX.pdf> (2004).
• Food and Drug Administration. Guidance for Industry: Pharmacogenomics Data Submission. Draft Guidance [online], <http://www.fda.gov/cder/guidance/5900dft.pdf> (2003).
• Meyer, U. A. Pharmacogenetics — five decades of therapeutic lessons from genetic diversity. Nature Rev. Genet. 5, 669–676 (2004).
  Article CAS Google Scholar
• Cytochrome P450 Drug Interaction Table. [online], <http://medicine.iupui.edu/flockhart/table.htm> (2004).
• Drug Topics.com. The top 200 brand-name drugs by unit in 2003 [online], <http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=104560> (2003).
• Drug Topics.com. The top 200 generic drugs by unit in 2003 [online], <http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=104565>(2003).
• Drug Topics.com. The top 200 brand-name drugs by retail sales in 2003 [online], <http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=104561> (2003).
• Drug Topics.com. The top 200 generic drugs by retail sales in 2003 [online], <http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id=104567> (2003).
• Elsevier Inc. MD Consult Core Collection [online], <http://www.mdconsult.com/> (2004).
• Klein, T. E. et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J. 1, 167–170 (2001).
  Article CAS Google Scholar
• Ingelman-Sundberg, M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedebergs Arch. Pharmacol. 369, 89–104 (2003).
  Article Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics — 2004 Update [online](2003).
• National Institute of Mental Health. NIH Publication No. 01-4584. The numbers count — mental disorders in America: a summary of statistics describing the prevalence of mental disorders in America [online], <http://www.nimh.nih.gov/publicat/numbers.cfm> (2001).
• National Academy on an Aging Society. Depression: a treatable disease — challenges for the 21st century: chronic and disabling conditions. Number 9. [online], <http://www.agingsociety.org/agingsociety/pdf/depression.pdf> (2000).
• Gibbons, R. J. et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina) [online], <http://www.acc.org/clinical/guidelines/stable/stable.pdf> (2002).
• American College of Cardiology & American Heart Association Inc. ACC/AHA/ESC Pocket Guidelines for the Management of Patients with Atrial Fibrillation [online](2002).
• DuPont, R. L., Rice, D. P., Shiraki, S. & Rowland, C. Economic costs of obsessive–compulsive disorder. Cited in Anxiety Disorders: Obsessive–Compulsive Disorder (MDchoice.com) [online], <http://mdchoice.com/Pt/consumer/anxOCD.asp> (1996).
• Pfizer. Zoloft OCD fact sheet [online], <http://www.zoloft.com/psd/factsheet/ocdfact.pdf> (2000).
• Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment (Number 11): Treatment of Attention-Deficit/Hyperactivity Disorder [online], <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1.chapter.14677> (1999).
• Chan, E., Zhan, C. & Homer, C. J. Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. 156, 504–11 (2002).
  Article Google Scholar
• Rice, D. P. The economic impact of schizophrenia. J. Clin. Psychiatry 60 (Suppl. 1), 28–30 (1999).
  Google Scholar
• Adams, P. F., Hendershot, G. E. & Marano, M. A. Current estimates from the National Health Interview Survey, 1996. National Center for Health Statistics. Vital Health Stat 10(200) [online], <http://www.cdc.gov/nchs/data/series/sr_10/10_200_1.pdf> (1999).
• Fendrick, A. M., Monto, A. S., Nightengale, B. & Sarnes, M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch. Intern. Med. 163, 487–494 (2003).
  Article Google Scholar
• Ospina, M. & Harstall, C. Prevalence of chronic pain: an overview HTA Report 29 [online], <http://www.ahfmr.ab.ca/hta/hta-publications/reports/prevalence_chronic_pain.pdf>(2002).
• Stewart, W. F., Ricci, J. A., Chee, E., Morganstein, D. & Lipton, R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA 290, 2443–2454 (2003).
  Article CAS Google Scholar
• Lethbridge-Çejku, M., Schiller, J. S. & Bernadel, L. Summary health statisticsfor US Adults: National Health Interview Survey, 2002. National Center for Health Statistics. Vital and Health Statistics Series 10 [online], <http://www.cdc.gov/nchs/data/series/sr_10/sr10_222.pdf> (2004).
• CDC & US Department of Health and Human Services. Preventing chronic diseases: investing wisely in health. screening to prevent cancer deaths [online], <http://www.cdc.gov/nccdphp/pe_factsheets/pefs_cancer.pdf> (2003).
• Altman, R. B. et al. Indexing pharmacogenetic knowledge on the World Wide Web. Pharmacogenetics 13, 3–5 (2003).
  Article Google Scholar
• US Public Health Service. Mental Health: A Report of the Surgeon General [online], <http://www.surgeongeneral.gov/library/mentalhealth/home.html> (1999).
• Pirmohamed, M. et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 329, 15–19 (2004).
  Article Google Scholar
• Gasche, Y. et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351, 2827–2831 (2004).
  Article CAS Google Scholar
• Higashi, M. K. & Veenstra, D. L. Managed care in the genomics era: assessing the cost-effectiveness of genetic tests. Am. J. Manage Care 9, 493–500 (2003).
  Google Scholar
• Ingelman-Sundberg, M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25, 193–200 (2004).
  Article CAS Google Scholar
• Collins, F. S., Green, E. D., Guttmacher, A. E. & Guyer, M. S. A vision for the future of genomics research. Nature 422, 835–847 (2003).
  Article CAS Google Scholar
• Evans, W. E. & Relling, M. K. Moving towards individualized medicine with pharmacogenomics. Nature 429, 464–468 (2004).
  Article CAS Google Scholar
• Zineh, I. et al. Availability of pharmacogenomics-based prescribing information in currently approved drugs. Pharmacogenomics J. 4, 354–8 (2004).
  Article CAS Google Scholar
• Kirchheiner, J. et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychol. 9, 442–73 (2004).
  Article CAS Google Scholar
• Klein, T. E. & Altman, R. B. PharmGKB: the pharmacogenetics and pharmacogenomics knowledge base. Pharmacogenomics J. 4, 1 (2004).
  Article CAS Google Scholar
• Drug Information Association. Co–Development of Drug, Biological, and Device Products (meeting announcement) [online], <http://www.diahome.org>(2004).
• Feigal, D. W. & Gutman, S. in Pharmacogenomics: Social, Ethical, and Clinical Dimensions (ed. Rothstein, M. A.) 99–108 (John Wiley & Sons, Inc, New Jersey, 2003).
  Book Google Scholar